Cameron Turtle - 02 Jan 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SYRE
Reported as of: 02 Jan 2026
Net transaction value: -$460,134
SEC form: 4
Accepted by SEC: 06 Jan 2026, 21:36:32 UTC
Prior SEC filing: 03 Dec 2025
Next SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Cameron Turtle filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 06 Jan 2026.

Key facts

This page summarizes Cameron Turtle's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 21:36.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: -$460,134.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001758363 Primary reporting owner

Turtle Cameron

Relationship: Chief Executive Officer, Director
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Sale

Transaction value: $387,243
Shares: -12,709
Change %: -1.9%
Price: $30.47
Shares after: 674,198
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3

SYRE transaction

Common Stock

Sale

Transaction value: $69,652
Shares: -2,191
Change %: -0.32%
Price: $31.79
Shares after: 672,007
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F3, F4

SYRE transaction

Common Stock

Sale

Transaction value: $3,239
Shares: -100
Change %: -0.01%
Price: $32.39
Shares after: 671,907
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.

Footnote F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.